← All trials
NCT05154383
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Sep 15, 2022
- Completion date
- Sep 15, 2022
- First posted
- Dec 13, 2021
- Last posted
- Dec 13, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CH AnnecyLead sponsor
- EurofinsCollaborator
- Sanofi-AventisCollaborator
- CH AnnecyOverall official - principal investigator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of LyonCollaborator
- EURAXI PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.